What is he best known for?
The fields of study he is best known for:
- Immune system
- Internal medicine
- Gene
Christian P. Larsen mainly focuses on Immunology, Transplantation, Immune system, T cell and Immunosuppression.
His Immunology research incorporates elements of Cytotoxic T cell and CD40.
His study in CD40 is interdisciplinary in nature, drawing from both Allograft rejection, Blockade, In vivo and Effector.
His Transplantation study combines topics from a wide range of disciplines, such as Regimen and Tolerance induction.
His Immune system research integrates issues from Organ transplantation and Heterologous.
His research integrates issues of Cellular immunity and Cell biology in his study of T cell.
His most cited work include:
- Long-term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways. (1361 citations)
- mTOR regulates memory CD8 T-cell differentiation (1090 citations)
- Rapid cloning of high-affinity human monoclonal antibodies against influenza virus (851 citations)
What are the main themes of his work throughout his whole career to date?
Christian P. Larsen mostly deals with Immunology, Transplantation, Belatacept, T cell and CD28.
His Immunology study integrates concerns from other disciplines, such as Cytotoxic T cell, CD40 and Blockade.
The various areas that Christian P. Larsen examines in his Blockade study include Cancer research, CD154, Monoclonal antibody and In vivo.
His research in Transplantation intersects with topics in Bone marrow, Immune tolerance and Islet.
His study in Belatacept is interdisciplinary in nature, drawing from both Regimen, Immunosuppression, Abatacept and Urology.
His T cell research is multidisciplinary, relying on both Major histocompatibility complex, Cytokine, Priming and Virology.
He most often published in these fields:
- Immunology (57.51%)
- Transplantation (41.08%)
- Belatacept (20.96%)
What were the highlights of his more recent work (between 2012-2021)?
- Belatacept (20.96%)
- Immunology (57.51%)
- Transplantation (41.08%)
In recent papers he was focusing on the following fields of study:
The scientist’s investigation covers issues in Belatacept, Immunology, Transplantation, Immunosuppression and Kidney transplantation.
His research in Belatacept intersects with topics in Calcineurin, Renal function, Regimen, Urology and Abatacept.
His Immunology study deals with Cytotoxic T cell intersecting with Toxicity and Cell biology.
As a member of one scientific family, he mostly works in the field of Transplantation, focusing on Diabetes mellitus and, on occasion, Clinical endpoint.
The Immunosuppression study combines topics in areas such as Clinical trial, Randomization, Tacrolimus, Kidney and Antibody.
His studies deal with areas such as Blockade and Cytokine as well as T cell.
Between 2012 and 2021, his most popular works were:
- Belatacept and Long-Term Outcomes in Kidney Transplantation. (369 citations)
- Phase 3 Trial of Transplantation of Human Islets in Type 1 Diabetes Complicated by Severe Hypoglycemia (256 citations)
- Long‐Term Belatacept Exposure Maintains Efficacy and Safety at 5 Years: Results From the Long‐Term Extension of the BENEFIT Study (144 citations)
In his most recent research, the most cited papers focused on:
- Immune system
- Internal medicine
- Gene
Immunology, Belatacept, Transplantation, Immunosuppression and Abatacept are his primary areas of study.
His work focuses on many connections between Immunology and other disciplines, such as Cytotoxic T cell, that overlap with his field of interest in CD8 and Toxicity.
His Belatacept study combines topics in areas such as CD28, Cell, Tacrolimus and Renal function.
His Transplantation study is concerned with the field of Internal medicine as a whole.
His Immunosuppression research integrates issues from Clinical trial, Surgery, Antibody and Urology.
His Abatacept study combines topics from a wide range of disciplines, such as Pharmacology and Sirolimus.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
